
Sanofi to axe 466 R&D positions in Germany and France
pharmafile | June 21, 2019 | News story | Medical Communications, Research and Development, Sales and Marketing | Sanofi, pharma
Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs across Germany and France as part of a “voluntary departure programme”.
The French drugmaker revealed the move as it aims to downscale its development of cardiovascular drugs in favour of work in the areas of immuno-oncology, vaccines and rare disease. The firm said it would no longer pursue new development projects in the cardiovascular and diabetes space, instead focusing only on its existing research programmes.
The 466 cuts will be taken up voluntarily by willing staff members. Sanofi currently employs over 100,000 staff worldwide, with 15,000 installed in R&D functions.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …






